Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

Overview of attention for article published in Cardiovascular Diabetology, February 2014

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 174 followers.

FDA is looking into this, but in this analysis: Onglyza (saxagliptin) is safe for #heart patients. http://t.co/9zJeB2IfaU

FDA is looking into this, but in this analysis: Onglyza (saxagliptin) is safe for #heart patients. http://t.co/Pxkqwre6QS

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.